Published
Reported in literature (not internally validated)
Predicted
Predicted reactive (based on sequence homology)
Not recommended
Not recommended (failed internal validation)
WB
IHC-P
FC(Intra)
IF-Cell
human
Product Features
Form
Liquid
Concentration
1 mg/mL.(The concentration of this product may be batch-dependent)
Lot Concentration Lookup
Storage Instructions
Store at 2-8℃. Avoid freeze.
Storage Buffer
PBS (pH7.4).
Isotype
IgG
Purification Method
Protein A affinity purified.
Application Dilution
Target
Function
The tumor necrosis factor (TNF) receptor family is composed of several type I integral membrane glycoproteins that exhibit homology in their cysteine-rich extracellular domains. Members of this family include FAS, OX40, CD27 and CD30. Ligands for these receptors are often type II transmembrane glycoproteins, as is the case for CD27 and CD30. CD27 is a homodimeric lymphocyte-specific surface antigen present on T and B lymphocytes. Activation of the CD3 complex via the T cell receptor for antigen leads to an increase in CD27 expression. Together, CD27 and its ligand, CD27L, generate co-stimulatory signals required for complete T cell activation. CD30 is a surface marker for neoplastic cells of the Hodgkin's lymphoma and related hematologic malignancies. CD30L has been shown to enhance the proliferation of the Hodgkin's cell line HDLM-2, but exerts antiproliferative effects on large cell anaplastic lymphoma cell lines.
Background References
1. Grimsholm O. CD27 on human memory B cells-more than just a surface marker. Clin Exp Immunol. 2023 Jul
2. Starzer AM et al. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020 Mar
This data was developed using HA724423, the same antibody clone in a different buffer formulation. Western blot analysis of CD27 on different lysates with Rabbit anti-CD27 antibody (HA724423) at 1/10,000 dilution.
Lane 1: Raji (Human Burkitt's lymphoma cells) cell lysate Lane 2: MCF7 (Human breast cancer cells) cell lysate Lane 3: Ramos (Human Burkitt's lymphoma cells) cell lysate Lane 4: Daudi (Human Burkitt's lymphoma cells) cell lysate Lane 5: THP-1 (Human acute monoblastic leukemia cells) cell lysate
Lysates/proteins at 10 µg/Lane. Exposure time: 12 seconds; ECL: K1801
MCF7 and THP-1 are negative controls (PMID: 11062504).
Blocking: 5% NFDM/TBST, 1 hour at room temperature Primary antibody: HA724423, 1/10,000 in primary antibody dilution buffer (K1803), overnight at 4 ℃ Secondary antibody: Goat anti-Rabbit IgG-HRP (HA1001), 1/50,000 in 5% NFDM/TBST, 1 hour at room temperature
Predicted band size: 29 kDa Observed band size: 50 kDa
☑ Relative expression (RE)
This data was developed using HA724423, the same antibody clone in a different buffer formulation. Application: Immunocytochemistry (IF-cell)
Species: Human
Sample: Raji (Human Burkitt's lymphoma cells) / MCF7 (Human breast cancer cells)
Fixation: 4% Paraformaldehyde, 15 minutes at room temperature.
Permeabilization: 0.1% Triton X-100, 15 minutes at room temperature.
Blocking: 1% BSA + 10% normal goat serum, 1 hour at room temperature.
Antibody dilution buffer: 1% BSA in PBST.
Primary antibody: HA724423, 1/2,000, overnight at 4°C.
Secondary antibody: Goat Anti-Rabbit IgG (iFluor™ 488, HA1121), 45 minutes at room temperature.
Counterstain: Beta tubulin (HA601187, red), 1/100, overnight at 4℃. The Nuclear counterstain was DAPI (Blue).
Negative control: MCF7 (PMID: 11062504).
This data was developed using HA724423, the same antibody clone in a different buffer formulation. Application: Immunohistochemistry (IHC-P)
Species: Human
Tissue: Tonsil
Sample: Paraffin-embedded section